kashi-health-logo

Kashi Clinical Laboratories
10101 SW Barbur Blvd, Suite 200
Portland, OR 97219

1 877 879-1815
1000 characters left

Contact Information

Other Information

Practice Information

Thank you for your interest in Kashi Health's genetic testing services.

Our genetic tests require guidance from a licensed healthcare provider. You may find a qualified provider from our list of approved professionals in the link below, or you may email your provider directly requesting that they contact us to request a genetic test. We wish you the best in your pursuit of healthy living.

1-877-879-1815

Graves' Disease

Graves' Disease is an autoimmune disease of the thyroid gland. It is characterized by hyperthyroidism associated with goiter, heart palpitations, bulging eyes, sweating, heat intolerance, tremor, anxiety and weight loss.

The immunological response in Graves' Disease comprises diffuse lymphocyte infiltration into the thyroid gland with thyroid stimulating immunoglobulin (TSI) autoantibody production. The hyperthyroidism is caused by activation of the thyroid stimulating hormone receptor (TSHR) by binding of autoantibodies.

Clinical Utility:

The most strongly associated gene implicated in Graves' disease is HLA-DRB1*03:01. Diagnosis is based on thyroid function tests as well as biochemical and clinical manifestations of hyperthyroidism rather than on genetic testing. Genetic testing does however contribute to a better understanding of the origin of the disease for improved diagnosis and treatment.

Method:

Kashi Clinical Laboratories utilizes a combination of PCR-SSO (polymerase chain reaction sequence specific oligonucleotide typing) and SBT (sequence based typing) for testing.

Kashi's in-house laboratory and experienced health professionals ensure that customer service is personal, timely, and tailored to every patient's needs.

What is the Next Step? 

Make Kashi Health's Genetic Testing part of your patient's treatment plan today. 

Questions? Please contact our customer service team at 877-879-1815 or 503-206-4989 or by email at This email address is being protected from spambots. You need JavaScript enabled to view it. . We are available Monday through Friday, from 8:00 AM - 5:00 PM, Pacific Time.

 References
  1. Bahn RS. Graves' ophthalmopathy. N Engl J Med. 2010; 362:726.
  2. Ban Y et al. Arginine at position 74 of the HLA-DR beta1 chain is associated with Graves' disease. Genes Immun. 2004; 5:203.
  3. Chen QY et al. HLA-DRB1*08, DRB1*03/DRB3*0101, and DRB3*0202 are susceptibility genes for Graves' disease in North American Caucasians, whereas DRB1*07 is protective. J Clin Endocrinol Metab. 1999; 84:3182.
  4. Grubeck-Loebenstein B et al. Retrobulbar T cells from patients with Graves' ophthalmopathy are CD8+ and specifically recognize autologous fibroblasts. J Clin Invest. 1994; 93:2738.
  5. Sekiguchi Y et al. Reverse 'see-saw' relationship between Graves' disease and myasthenia gravis; clinical and immunological studies. J Med Dent Sci. 2005; 52:43.